Sulbactam/Durlobactam: First Approval.

Article Details

Citation
Copy to clipboard

Keam SJ

Sulbactam/Durlobactam: First Approval.

Drugs. 2023 Sep;83(13):1245-1252. doi: 10.1007/s40265-023-01920-6.

PubMed ID
37523122 [ View in PubMed
]
Abstract

Sulbactam/durlobactam (XACDURO((R))), is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Coadministration of durlobactam (a beta-lactamase inhibitor with potent activity against a broad range of serine beta-lactamases) with sulbactam (an established class A beta-lactamase inhibitor with antibacterial activity against A. baumannii) prevents sulbactam degradation by ABC-produced beta-lactamases. In May 2023, sulbactam/durlobactam was approved in the USA for use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of ABC. This article summarizes the milestones in the development of sulbactam/durlobactam leading to this first approval for the treatment of infections caused by ABC.

DrugBank Data that Cites this Article

Drugs